Geoffrey M Duyk's Net Worth

$21.2 Million

Estimate Recalculated May 17, 2024 07:00PM EST

Who is Geoffrey M Duyk?

Geoffrey M Duyk has an estimated net worth of $21.2 Million. This is based on reported shares across multiple companies, which include AMYRIS, INC., EXELIXIS INC, AERIE PHARMACEUTICALS INC, REPLIDYNE INC, and EPIRUS Biopharmaceuticals, Inc..

SEC CIK

Geoffrey M Duyk's CIK is 0001202090

Past Insider Trading and Trends

2003 was Geoffrey M Duyk's most active year for acquiring shares with 5 total transactions. Geoffrey M Duyk's most active month to acquire stocks was the month of July. 2003 was Geoffrey M Duyk's most active year for disposing of shares, totalling 33 transactions. Geoffrey M Duyk's most active month to dispose stocks was the month of September. 2017 saw Geoffrey M Duyk paying a total of $778,131.50 for 58,167 shares, this is the most they've acquired in one year. In 2017 Geoffrey M Duyk cashed out on 116,334 shares for a total of $2,717,739.84, their largest year based on trade value.

Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!

AMYRIS, INC. (AMRSQ) Snapshot price: $0.001

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
-100.00%
-40.55K
—
—
0
May 7
Form 4
—
0
—
—
120.55K
Jan 3
Form 4
+466.36%
80K
—
—
97.15K
Aug 22
Form 4
+31.63%
9.74K
—
—
40.55K
Jan 18
Form 4
+31.67%
7.41K
—
—
30.81K
Aug 23
Form 4
+69.16%
9.57K
—
—
23.4K
Aug 5
Form 4
+224.24%
9.57K
—
—
13.83K
Oct 23
Form 4
+120.69%
35K
—
—
64K
Nov 3
Form 4
+141.67%
17K
—
—
29K
Jul 13
Form 4
+33.33%
3K
—
—
12K
Jul 30
Form 4
+50.00%
3K
—
—
9K
Aug 6
Form 4
+100.00%
3K
—
—
6K
Aug 1
Form 4
∞
3K
—
—
3K
Jul 19
Form 4
—
0
—
—
0
May 7
Form 3
—
0
—
—
0
Form 4
—
0
—
—
0
Mar 15
Form 3
—
0
—
—
0
No matching records found

EXELIXIS INC (EXEL) Snapshot price: $20.205

Pres R&D & CSO

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
-0.33%
-3.10K
$7.73
-$23,970.73
941.36K
Nov 4
Form 4
—
0
—
—
0
Oct 30
Form 4
-0.32%
-3.00K
$7.73
-$23,190.00
944.46K
Oct 31
Form 4
-0.42%
-4.00K
$7.93
-$31,717.13
947.46K
Oct 13
Form 4
-2.56%
-25.00K
$7.93
-$198,183.60
951.46K
Sep 18 - Oct 9
Form 4
—
0
—
—
0
Form 4
—
0
—
—
0
Form 4
—
0
—
—
0
Form 4
—
0
—
—
0
Form 4
—
0
—
—
0
Form 4
—
0
—
—
0
Form 4
—
0
—
—
0
Form 4
—
0
—
—
0
Form 4
—
0
—
—
0
No matching records found

AERIE PHARMACEUTICALS INC No price found

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
—
0
$30.05
-$1,939,608.34
3.4K
Feb 14 - Feb 15
Form 4
+100.00%
1.7K
—
—
3.4K
Jun 8
Form 4
∞
1.7K
—
—
1.7K
Apr 10
Form 4
—
0
—
—
0
Jun 11
Form 3/A
—
0
—
—
0
Form 3
—
0
—
—
0
No matching records found

REPLIDYNE INC No price found

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
—
0
—
—
0
Form 4
—
0
—
—
0
May 8
Form 4
—
0
—
—
0
Jun 28
Form 3
—
0
—
—
0
No matching records found

EPIRUS Biopharmaceuticals, Inc. No price found

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
—
0
—
—
0
Jun 5
Form 3
—
0
—
—
0
No matching records found